This house believes that low-dose intravenous cyclophosphamide is superior to standard high-dose regimes for treatment of lupus nephritis

Rheumatology

Volumn 44, Issue 3, 2005, Pages 398-401

  Gorman, C ^a   Bhatia, A ^a   Rahman, A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; GOSERELIN; LEUPRORELIN; METHYLPREDNISOLONE; PREDNISOLONE;

AMENORRHEA; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG SAFETY; FOLLOW UP; HERPES ZOSTER; HUMAN; INFECTION RATE; INTERMETHOD COMPARISON; KIDNEY FUNCTION; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; OVARY INSUFFICIENCY; PNEUMONIA; PRIORITY JOURNAL; REMISSION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; URINARY TRACT INFECTION;

CYCLOPHOSPHAMIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; LUPUS NEPHRITIS; PULSE THERAPY, DRUG; TREATMENT OUTCOME;

EID: 14944360665     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keh440     Document Type: Article

References (19)

1. Mok CC, Wong RWS, Lai KN. Treatment of severe proliferative lupus nephritis: the current state. Ann Rheum Dis 2003;62:799-804.
2. Dooley MA, Hogan S, Jennnette C, Falk R for the Glomerular Disease Collaborative Network. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Kidney Int 1997;51:1188-95.
3. Boumpas DT, Austin HA, Vaughn EM et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340:741-5.
4. Gourley MF, Austin HA, Scott D et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomised controlled trial. Ann Intern Med 1996;125:549-57.
5. Illei GG, Austin HA, Crane M et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001;135:248-57.
6. Chan TM, Li FK, Tang CSO et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000;343:1156-62.
7. Contreras G, Pardo V, Leclercq B et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350:971-80.
8. Austin HA, Klippel JH, Balow JE et al. Therapy of lupus nephritis: controlled trial of prednisolone and cytotoxic drugs. N Engl J Med 1986;314:614-19.
9. Houssiau FA, D'Cruz DP, Haga HJ, Hughes GR. Short course of weekly low-dose intravenous pulse cyclophosphamide in the treatment of lupus nephritis: a preliminary study. Lupus 1991;1:31-5.
10. Martin-Suarez I, D'Cruz D, Mansoor M, Fernandes AP, Khamashta MA, Hughes GR. Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. Ann Rheum Dis 1997;56:481-7.
11. Stojanovich L, Stoyanovich R, Kostich V, Dzjolich E. Neuropsychiatric lupus favourable response to low dose i.v. cyclophosphamide and prednisolone (pilot study). Lupus 2003;12:3-7.
12. Houssiau FA, Vasconcelos C, D'Cruz D et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomised trial of low-dose versus high-dose cyclophosphamide. Arthritis Rheum 2002;46:2121-31.
13. Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisolone only. Arthritis Rheum 1991;34:945-50.
14. Decker JL, Klippel JH, Plotz PH, Steinberg AD. Cyclophosphamide or azathioprine in lupus glomerulonephritis. A controlled trial: results at 28 months. Ann Intern Med 1975;83:606-15.
15. Block JA. Efficacy of low-dose versus high-dose cyclophosphamide in lupus nephritis: comment on the article by Houssiau et al. Arthritis Rheum 2003;48:1466.
16. Boumpas DT, Austin HA, Vaughan EM, Yarboro CH, Klippel JH, Balow JE. Risk for sustained amenorrhoea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993;119:366-9.
17. Hebert LA. Management of lupus nephropathy. Nephron Clin Pract 2003;93:c7-c12.
18. Blumenfeld Z, Shapiro D, Steinberg M, Avivi I, Nahir M. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus 2000;9:401-5.
19. Leandro MJ, Edwards JC. Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002;46: 2673-7.